.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Cerilliant
Medtronic
Johnson and Johnson
Deloitte
Merck
Mallinckrodt
Citi
Fuji
Daiichi Sankyo

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,207,127

« Back to Dashboard

Which drugs does patent 8,207,127 protect, and when does it expire?


Patent 8,207,127 protects KYPROLIS and is included in one NDA. There has been one Paragraph IV challenge on Kyprolis.

This patent has sixty-nine patent family members in twenty-four countries.

Summary for Patent: 8,207,127

Title:Compounds for enzyme inhibition
Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
Inventor(s): Smyth; Mark S. (Foster City, CA), Laidig; Guy J. (Menlo Park, CA)
Assignee: Onyx Technologies, Inc. (South San Francisco, CA)
Application Number:13/334,544
Patent Claim Types:
see list of patent claims
Use; Device; Composition; Formulation; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Onyx Therap
KYPROLIS
carfilzomib
POWDER;INTRAVENOUS202714-002Jun 3, 2016RXYesNo► Subscribe► Subscribe TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
Onyx Therap
KYPROLIS
carfilzomib
POWDER;INTRAVENOUS202714-001Jul 20, 2012RXYesYes► Subscribe► Subscribe TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,207,127

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,232,818Compounds for enzyme inhibition► Subscribe
8,129,346Compounds for enzyme inhibition► Subscribe
8,198,270Compounds for proteasome enzyme inhibition► Subscribe
8,207,126Compounds for enzyme inhibition► Subscribe
8,207,125Compounds for enzyme inhibition► Subscribe
8,207,297Compounds for enzyme inhibition► Subscribe
8,324,174Compounds for enzyme inhibition► Subscribe
8,207,124Compounds for enzyme inhibition► Subscribe
7,491,704Compounds for enzyme inhibition► Subscribe
7,417,042Compounds for enzyme inhibition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,207,127

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria494298► Subscribe
Austria496062► Subscribe
Australia2005238445► Subscribe
Australia2005271232► Subscribe
Australia2005295183► Subscribe
Australia2012203602► Subscribe
Australia2012211349► Subscribe
BrazilPI0509879► Subscribe
BrazilPI0514102► Subscribe
Canada2562411► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
UBS
Boehringer Ingelheim
US Department of Justice
Merck
Chinese Patent Office
Express Scripts
Baxter
Fish and Richardson
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot